Poonam Gera
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Poonam Gera has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Amit Dutt
Integrated Cancer Genomics Laboratory, Department of Genetics, University of Delhi South Campus, New Delhi, India
36 shared publications - Dimple Bhatia
Hypoxia and Clinical Genomics Lab (Clinician Scientist Laboratory), Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India
36 shared publications - Nilesh Gardi
Hypoxia and Clinical Genomics Lab (Clinician Scientist Laboratory), Advanced Centre for Treatment, Research, and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India
36 shared publications - Nita Nair
Apollo Hospital, Navi Mumbai, India
36 shared publications - Rajendra Badwe
Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India
36 shared publications - Rasika Kadam
Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai, Maharashtra, India
36 shared publications
Latest Publications
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
High MUC2 expression is associated with resistance to therapy.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
High MUC2 expression is associated with resistance to therapy.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing on SRCC PDO models.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing on SRCC PDO models.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Characterization of mucin-high PDX models over the passage.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Characterization of mucin-high PDX models over the passage.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Drug toxicity testing in SRCC PDO models.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
The genetic characterization of the patient samples
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
The genetic characterization of the patient samples
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Different media compositions used for the culture of SRCC organoids. 8 different culture media with different growth factors and small molecule inhibitors were used for the optimization of SRCC colon and rectal organoids.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Different media compositions used for the culture of SRCC organoids. 8 different culture media with different growth factors and small molecule inhibitors were used for the optimization of SRCC colon and rectal organoids.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Catalog number, company name, and dilutions of antibodies used for Western blotting and immunofluorescence.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Catalog number, company name, and dilutions of antibodies used for Western blotting and immunofluorescence.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Number of passages of the PDX and PDO models generated in this study.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Number of passages of the PDX and PDO models generated in this study.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Reagents tested for human intestinal organoid culture optimization. Different reagents stock and final concentration used for the growth of organoids
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas
Reagents tested for human intestinal organoid culture optimization. Different reagents stock and final concentration used for the growth of organoids